A Retrospective Observational Study of Adult and Pediatric Patients With Thrombotic Microangiopathy (TMA) After Hematopoietic Stem Cell Transplant (HSCT)
试验速览
- 阶段
- 不适用
- 状态
- 撤回
- 试验地点
- 1
- 主要终点
- Proportion of patients achieving TMA Response
研究概览
简要总结
This is an observational, retrospective study designed to assess outcomes in patients diagnosed with hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA) who were not treated with complement component (C5) inhibitor therapy. Data required to evaluate study outcomes will be abstracted from the medical records of all patients who meet study eligibility criteria.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Only
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 1 Month 至 —（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Body weight ≥ 5 kg at the time of HSCT-TMA diagnosis
- •Documented TMA diagnosis within 6 months from the HSCT
- •Evidence of renal dysfunction
- •Presence of hypertension
排除标准
- •History or presence of familial or acquired 'a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13' (ADAMTS13) deficiency (activity < 5%)
- •Shiga toxin-related hemolytic uremic syndrome (ST-HUS)
- •Positive direct Coombs test
- •Diagnosis of disseminated intravascular coagulation
- •History or presence of bone marrow/graft failure
- •Diagnosis of veno-occlusive disease
- •Received a complement inhibitor (eg, eculizumab) post-HSCT through 12 months post TMA diagnosis
结局指标
主要结局
Proportion of patients achieving TMA Response
时间窗: During the 26-week period after HSCT-TMA diagnosis
TMA Response is defined as platelet count ≥ 50,000/mm\^3, lactate dehydrogenase \< 1.5 upper limit of normal, absence of schistocytes (if present at baseline), and increase in eGFR ≥ 30% from baseline or discontinuation of dialysis (for patients on dialysis at baseline)
次要结局
- Proportion of patients achieving TMA response(During the 52-week period after HSCT-TMA diagnosis)
- Changes in individual components of TMA response(From baseline to 26 weeks and to 52 weeks after HSCT-TMA diagnosis)
- Overall survival(At 26 weeks and 52 weeks after HSCT-TMA diagnosis)
- Nonrelapse mortality(At 26 weeks and 52 weeks after HSCT-TMA diagnosis)